These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17884638)

  • 1. Rapidly reversible hydrophobization: an approach to high first-pass drug extraction.
    Monahan SD; Subbotin VM; Budker VG; Slattum PM; Neal ZC; Herweijer H; Wolff JA
    Chem Biol; 2007 Sep; 14(9):1065-77. PubMed ID: 17884638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrug strategies in anticancer chemotherapy.
    Kratz F; Müller IA; Ryppa C; Warnecke A
    ChemMedChem; 2008 Jan; 3(1):20-53. PubMed ID: 17963208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828.
    Binderup E; Björkling F; Hjarnaa PV; Latini S; Baltzer B; Carlsen M; Binderup L
    Bioorg Med Chem Lett; 2005 May; 15(10):2491-4. PubMed ID: 15863303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loco-regional cancer drug therapy: present approaches and rapidly reversible hydrophobization (RRH) of therapeutic agents as the future direction.
    Budker VG; Monahan SD; Subbotin VM
    Drug Discov Today; 2014 Dec; 19(12):1855-70. PubMed ID: 25173702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-time monitoring of drug release.
    Weinstain R; Segal E; Satchi-Fainaro R; Shabat D
    Chem Commun (Camb); 2010 Jan; 46(4):553-5. PubMed ID: 20062859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption.
    Huttunen KM; Mannila A; Laine K; Kemppainen E; Leppänen J; Vepsäläinen J; Järvinen T; Rautio J
    J Med Chem; 2009 Jul; 52(14):4142-8. PubMed ID: 19522462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.
    Ansell SM; Johnstone SA; Tardi PG; Lo L; Xie S; Shu Y; Harasym TO; Harasym NL; Williams L; Bermudes D; Liboiron BD; Saad W; Prud'homme RK; Mayer LD
    J Med Chem; 2008 Jun; 51(11):3288-96. PubMed ID: 18465845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do prodrugs deliver?
    Smith DA
    Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and characterization of a novel liver-targeted prodrug of cytosine-1-beta-D-arabinofuranoside monophosphate for the treatment of hepatocellular carcinoma.
    Boyer SH; Sun Z; Jiang H; Esterbrook J; Gómez-Galeno JE; Craigo W; Reddy KR; Ugarkar BG; MacKenna DA; Erion MD
    J Med Chem; 2006 Dec; 49(26):7711-20. PubMed ID: 17181153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive physiologically based pharmacokinetic model for antibody-directed enzyme prodrug therapy.
    Fang L; Sun D
    Drug Metab Dispos; 2008 Jun; 36(6):1153-65. PubMed ID: 18356268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger.
    Gopin A; Pessah N; Shamis M; Rader C; Shabat D
    Angew Chem Int Ed Engl; 2003 Jan; 42(3):327-32. PubMed ID: 12548691
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody-directed enzyme prodrug therapy: a promising approach for a selective treatment of cancer based on prodrugs and monoclonal antibodies.
    Tietze LF; Krewer B
    Chem Biol Drug Des; 2009 Sep; 74(3):205-11. PubMed ID: 19660031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT.
    Kamal A; Tekumalla V; Krishnan A; Pal-Bhadra M; Bhadra U
    ChemMedChem; 2008 May; 3(5):794-802. PubMed ID: 18247436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
    O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ cross-linkable high molecular weight hyaluronan-bisphosphonate conjugate for localized delivery and cell-specific targeting: a hydrogel linked prodrug approach.
    Varghese OP; Sun W; Hilborn J; Ossipov DA
    J Am Chem Soc; 2009 Jul; 131(25):8781-3. PubMed ID: 19499915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
    Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
    Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
    Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
    MacKenna DA; Montag A; Boyer SH; Linemeyer DL; Erion MD
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):981-91. PubMed ID: 19283354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
    Trédan O; Garbens AB; Lalani AS; Tannock IF
    Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.